Comparison of lornoxicam and rofecoxib in patients with activated osteoarthritis (COLOR study)

Clinical Drug Investigation

Volumn 24, Issue 4, 2004, Pages 227-236

  Rose, Peter ^a   Steinhauser, Christine ^a  

^a TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; INDOMETACIN; LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ROFECOXIB; TRAMADOL;

ADOLESCENT; ADULT; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MUCOSA INFLAMMATION; NAUSEA; OSTEOARTHRITIS; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SCHOOL CHILD; VOMITING;

EID: 1842739956     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424040-00004     Document Type: Article

References (20)

1. Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S18-21
2. Ferber HP, Maleschitz P, Binder D. Chlortenoxicam, a new NSAID, prevents the arachidonic acid-induced toxicity [abstract A387]. 2nd World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators; 1986 Mar 19-20, Monte Carlo
3. Adams SS. Non-steroidal anti-inflammatory drugs, plasma half-lives and adverse reactions [letter]. Lancet 1987; II: 1204-5
4. Futaki N, Takahashi S, Kitagawa T, et al. Anti-inflammatory, analgesic, antipyretic and cyclooxygenase inhibitory effects of a non-steroidal anti-inflammatory agent lornoxicam (in Japanese). Jpn Pharmacol Ther 1997; 25: 55-71
5. Berg J, Christoph T, Widerna M, et al. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J Pharmacol Toxicol Methods 1997; 37: 179-86
6. Brune K, Hinz B. Selektive Cyclooxygenase-2-Hemmer: Glaube, Hoffnung, Realität. Akt Rheumatol 1998; 23: 1-5
7. Beejay U, Wolfe MM. Cyclooxygenase-2-selective inhibitors: panacea or flash in the pan? Gastroenterology 1999; 117: 1002-5
8. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996 Apr; 51 (4): 639-57
9. Berry H, Ollier S. Lornoxicam in clinical practice. Postgrad Med J 1990; 66 Suppl. 4: S41-5
10. Bias P. Efficacy and safety of lornoxicam (8mg b.i.d.) in comparison with placebo in patients with osteoarthritis of the knee: a four-week, randomized, prospective multicentre, double-blind, placebo-controlled, parallel-group phase IIb study (study CT 94). Nycomed Pharma A/S, 1995 (Data on file)
11. Caruso I, Montrone F, Boari L. et al. Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multicenter study. Adv Ther 1994; 11: 132-8
12. Krimmer J. A multicentre, randomized, double-blind, parallel group design study comparing the effects of multiple doses of lornoxicam versus diclofenac in patients with rheumatoid arthritis during a three month period followed by a continuation of treatment in an open design in those patients receiving lornoxicam for a period of nine months (study CT 39). Nycomed Pharma A/S, 1993 (Data on file)
13. Norholt SE, Sindet-Petersen S, Bugge C, et al. A randomized, double-blind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. J Clin Pharmacol 1995 Jun; 35: 606-14
14. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287 (1): 64-71
15. Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996; 23 (9): 1605-11
16. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Athritis Rheum 2000; 43: 978-87
17. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis: Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160 (12): 1781-7
18. Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110: 13-9
19. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celexocib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8 (2): 85-95
20. Graves JW, Hunder IA. Worsening of hypertension by cyclooxygenase-2- inhibitors. J Clin Hypertens 2000; 2 (6): 396-8